

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

- a) Consultation comments indicated that EGFR-mutation-positive NSCLC has a higher incidence in people of Asian origin and in females.
- b) Consultation comments noted that the clinical trial for aumolertinib only included people from China and so the applicability of this trial to the UK population is difficult to establish.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

- a) The committee should consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.
- b) The committee will consider the generalisability of the trial data to UK clinical practice when making its recommendation. This is not considered an equality issue.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

N/A

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Jasdeep Hayre

Date: 29/11/2021